Research Use Only - Not for human consumption. 18+ only.

IGF-1 LR3 vs Follistatin

Evidence-based comparison · Updated 2026

Summary

IGF-1 LR3 drives muscle growth and fat loss through sustained IGF-1 receptor activation, making it suited for researchers studying anabolic signaling and body composition. Follistatin works by removing myostatin-mediated suppression of muscle growth, producing more targeted hypertrophic effects. Researchers focused on protein synthesis pathways may prefer IGF-1 LR3, while those studying myostatin inhibition and muscle mass ceilings may find Follistatin more relevant.

Side-by-Side Comparison

IGF-1 LR3Follistatin
EvidenceCGrade CPrimarily animal or in-vitro studies; limited human dataCGrade CPrimarily animal or in-vitro studies; limited human data
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits
  • +Promotes significant muscle growth
  • +Enhances fat loss
  • +Improves recovery from exercise
  • +Increases protein synthesis
  • +May improve nutrient partitioning
  • +Inhibits myostatin
  • +Dramatic increase in muscle mass
  • +Increases strength significantly
  • +May improve metabolic health
  • +Reduces body fat
Dosage20-100 mcg mcg — Daily for maximum 4 weeks100-300 mcg mcg — Every other day or 2x weekly
RouteSubcutaneous, IntramuscularIntramuscular
CategoryMuscle Growth & PerformanceMuscle Growth & Performance

Full research page

IGF-1 LR3 →

Full research page

Follistatin →

Which Should You Choose?

IGF-1 LR3 acts directly on the IGF-1 receptor to drive anabolic and metabolic effects, while Follistatin works upstream by neutralizing myostatin, a natural brake on muscle growth. These are complementary rather than redundant mechanisms.

Choose IGF-1 LR3 when:

  • +Research focus includes both muscle hypertrophy and fat loss simultaneously, as IGF-1 LR3 promotes lipolysis alongside anabolic signaling
  • +Interest in studying protein synthesis, glucose uptake, and nutrient partitioning at the cellular level
  • +Protocol requires a well-characterized half-life and receptor binding profile, given IGF-1 LR3's documented 20-30x longer bioactivity versus native IGF-1

Choose Follistatin when:

  • +Research objective centers on myostatin inhibition specifically, to study the upper limits of skeletal muscle mass
  • +Focus on muscle-wasting conditions where removing myostatin suppression may have greater mechanistic relevance than direct anabolic receptor stimulation
  • +Interest in strength and hypertrophy outcomes driven by a distinct pathway independent of the IGF-1 axis

Stacking IGF-1 LR3 with Follistatin is explored in some research contexts given their non-overlapping mechanisms, though combined safety and interaction data in humans remain limited.

Frequently Asked Questions

Do IGF-1 LR3 and Follistatin target the same muscle growth pathway?⌄
No, they operate through distinct mechanisms. IGF-1 LR3 activates the IGF-1 receptor to directly stimulate protein synthesis and inhibit protein breakdown. Follistatin works by binding and neutralizing myostatin, a negative regulator that suppresses muscle growth. Because these pathways are independent, their effects do not directly overlap and may theoretically be additive in a research context.
Which peptide is likely to produce faster observable effects in research models?⌄
IGF-1 LR3 has a well-documented extended half-life and direct receptor activity, which may produce measurable anabolic effects relatively quickly in animal models. Follistatin's timeline depends on how rapidly myostatin suppression translates to tissue-level hypertrophy, a process that in animal studies has shown significant muscle mass changes over several weeks. Neither peptide has established human clinical timelines at this stage of research.
Is it scientifically rational to stack IGF-1 LR3 with Follistatin?⌄
From a mechanistic standpoint, combining these peptides targets two different points in muscle growth regulation, direct anabolic receptor stimulation via IGF-1 LR3 and removal of myostatin-mediated inhibition via Follistatin. This dual-pathway approach is theoretically complementary, and some preclinical research contexts explore such combinations. However, interaction data, combined safety profiles, and dosing parameters for a stack have not been established in human trials, making this an area of active research interest rather than established protocol.
How do the evidence grades compare between IGF-1 LR3 and Follistatin?⌄
Both peptides carry a Grade C evidence rating, meaning current support is largely derived from preclinical animal studies and in vitro research, with limited or absent controlled human trial data. Neither has regulatory approval for therapeutic use, and both are classified as research-only compounds. Researchers should weight conclusions from existing studies carefully given the absence of robust human clinical evidence for either agent.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin